#United States #Charlottesville #RIVANNA #Accuro #Neuraxial

RIVANNA Introduces Major Advancements in Neuraxial Procedures

In a groundbreaking development, RIVANNA®, a leader in AI-driven clinical decision-support solutions, recently announced that the Centers for Medicare & Medicaid Services (CMS) has established a new ICD-10-PCS procedure code. This code, XEZU3HC, will come into effect on October 1, 2026, marking a significant milestone for the field of neuraxial anesthesia.

Understanding the New Code

The newly implemented code specifically identifies procedures involving computer-aided intraprocedural navigation using real-time ultrasound imaging with continuous needle tracking. Prior to this innovation, traditional coding methods did not separately account for the use of ultrasound navigation during such sensitive anesthetic practices, often leading to a lack of visibility around these procedures in hospital records. The introduction of XEZU3HC allows healthcare facilities to better document and track the implementation of advanced navigational techniques in their neuraxial procedures.

Importance of Accurate Documentation

The significance of this change cannot be understated. Hospitals previously relied on existing codes for basic neuraxial anesthesia, but the nuances provided by advanced ultrasound guidance went unrecorded. The XEZU3HC code not only represents a way to standardize and track these specialized procedures but also lays the groundwork for future evaluations of their clinical and economic impact. Given the serious complications associated with unintended dural puncture—which affects 0.5% to 1.5% of labor epidural placements—this enhanced documentation is crucial. Recent studies show that a significant percentage of patients with accidental dural punctures continue to suffer from headaches long after the procedure, highlighting the need for rigorous tracking and evaluation of outcomes.

Accuro® 3S: Setting New Standards

At the forefront of this advancement is RIVANNA's flagship product, Accuro® 3S. This sophisticated ultrasound system, which is the first of its kind to gain FDA clearance for real-time neuraxial guidance, employs advanced features such as automated anatomical guidance through its SpineNav-AI technology, as well as innovative needle tracking via SafeTrack. Such technology not only enhances the accuracy of needle placement but also significantly reduces the margin of error during sensitive procedures.

“The Accuro 3S was engineered to provide real-time guidance during neuraxial procedures,” stated Will Mauldin, PhD, co-founder and CEO of RIVANNA. “The establishment of the XEZU3HC code means that the procedural advancements we've implemented will no longer be obscured in hospital data. It enables hospitals to uniquely identify and evaluate these navigational techniques in the context of patient outcomes.”

Code Placement and Future Implications

The CMS classification places the XEZU3HC code in the New Technology category under the newly created XEZ table, indicating its procedural uniqueness while not tethering it to a specific product or company. This code does not automatically imply separate payment from insurance but establishes a framework for consistent identification of procedures. The goal is to gather real-world evidence that can inform future discussions regarding reimbursement and effectiveness in a clinical setting.

“Neuraxial procedures have traditionally been performed based heavily on tactile feedback, making complications difficult to track in national data,” added Dr. Delphine Le Roux, Senior Director at RIVANNA. “With this new identification code, we can accurately assess the impact of real-time guidance technology on patient safety and procedural effectiveness.”

Looking ahead, RIVANNA aims to incorporate the XEZU3HC code into its outcomes framework to drive further analysis of its implications on clinical practices. This will enhance the understanding of how advanced navigational techniques transform spine-related anesthesia practices and contribute to safer patient experiences.

About RIVANNA

RIVANNA stands as a pioneering medical technology firm, focusing on the development of clinical decision-support tools that leverage proprietary clinical datasets and advanced AI-driven methods. Headquartered in Charlottesville, Virginia, RIVANNA boasts an impressive portfolio of FDA-cleared products and a robust collection of patents reinforcing its commitment to innovation in medical technology. With a clear mandate of expanding access to advanced medical capabilities, RIVANNA continues to redefine the landscape of integrative medical solutions for interventional guidance and trauma triage, starting with neuraxial procedures and extending to musculoskeletal assessments.